Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• Announced the effective date for a reverse stock split, with trading on a split-adjusted basis beginning August 24, 2026.

• Common stock will continue trading under the existing ticker symbol, with a new CUSIP number assigned post-split.

• Forward-looking statements address the anticipated timing of the Redx Pharma acquisition and related shareholder meeting.

• Risks include regulatory approvals, integration challenges, and potential impacts on stock price and operations.

Voting matters and shareholder proposals

• Proxy statement to be filed for shareholder approval of the proposed acquisition of Redx Pharma.

• Shareholders urged to review proxy materials for important information regarding the transaction.

Shareholder rights and capital structure

• Reverse stock split will modify the rights of security holders, effective August 24, 2026.

• Common stock will remain listed on Nasdaq, subject to compliance with minimum bid price requirements.